Literature DB >> 30705864

Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy-fortune favours the bold.

Surein Arulananda1,2,3, Paul Mitchell1,3,4.   

Abstract

Entities:  

Year:  2018        PMID： 30705864      PMCID： PMC6328698          DOI： 10.21037/tlcr.2018.08.12

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  27 in total

1.  RTOG 0214: a phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer.

Authors:  Elizabeth Gore
Journal:  Clin Adv Hematol Oncol       Date:  2005-08

2.  Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B.

Authors:  Caio Max S Rocha Lima; James E Herndon; Michael Kosty; Gerald Clamon; Mark R Green
Journal:  Cancer       Date:  2002-01-01       Impact factor: 6.860

3.  Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group.

Authors:  G Clamon; J Herndon; R Cooper; A Y Chang; J Rosenman; M R Green
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

Review 4.  Geriatric oncology: challenges for the new century.

Authors:  L Balducci
Journal:  Eur J Cancer       Date:  2000-09       Impact factor: 9.162

5.  Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial.

Authors:  M A Socinski; J G Rosenman; J Halle; M J Schell; Y Lin; S Russo; M P Rivera; J Clark; S Limentani; R Fraser; W Mitchell; F C Detterbeck
Journal:  Cancer       Date:  2001-09-01       Impact factor: 6.860

6.  Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160).

Authors:  Valerie W Rusch; Dorothy J Giroux; Michael J Kraut; John Crowley; Mark Hazuka; Timothy Winton; David H Johnson; Lawrence Shulman; Frances Shepherd; Claude Deschamps; Robert B Livingston; David Gandara
Journal:  J Clin Oncol       Date:  2007-01-20       Impact factor: 44.544

7.  High-dose radiation therapy for elderly patients with inoperable or unresectable non-small cell lung cancer.

Authors:  K Hayakawa; N Mitsuhashi; S Katano; Y Saito; Y Nakayama; H Sakurai; T Akimoto; M Hasegawa; M Yamakawa; H Niibe
Journal:  Lung Cancer       Date:  2001-04       Impact factor: 5.705

8.  Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019.

Authors:  Kathy S Albain; John J Crowley; Andrew T Turrisi; David R Gandara; William B Farrar; Joseph I Clark; Kristie R Beasley; Robert B Livingston
Journal:  J Clin Oncol       Date:  2002-08-15       Impact factor: 44.544

9.  The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly.

Authors:  Steven E Schild; Philip J Stella; Susan M Geyer; James A Bonner; William L McGinnis; James A Mailliard; Jeffery Brindle; Aminah Jatoi; James R Jett
Journal:  J Clin Oncol       Date:  2003-07-21       Impact factor: 44.544

10.  Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer.

Authors:  C Schaake-Koning; W van den Bogaert; O Dalesio; J Festen; J Hoogenhout; P van Houtte; A Kirkpatrick; M Koolen; B Maat; A Nijs
Journal:  N Engl J Med       Date:  1992-02-20       Impact factor: 91.245
View more
  1 in total

1.  Feasibility and safety of PD-1/L1 inhibitors for non-small cell lung cancer in front-line treatment: a Bayesian network meta-analysis.

Authors:  Hengrui Liang; Guo Lin; Wei Wang; Jun Huang; Yilin Yang; Yuting Lan; Runchen Wang; Fei Cui; Zhexue Hao; Hongsheng Deng; Shen Zhao; Bo Cheng; Shan Xiong; Jianfu Li; Caichen Li; Jun Liu; Jianxing He; Wenhua Liang
Journal:  Transl Lung Cancer Res       Date:  2020-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.